Navigation Links
Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Date:11/6/2009

PARIS, November 6 /PRNewswire/ --

- Trial Will Compare NXL103 With Leading Oral Agent Linezolid for the Treatment of Multi-Resistant Staphylococcus Aureus (MRSA) Infections

Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces today that its most advanced oral antibacterial NXL103 (flopristin/linopristin), has started a Phase II clinical trial in adults with acute bacterial skin and skin structure infections (ABSSSI). The trial is designed to assess the safety and efficacy of NXL103 in comparison to oral linezolid (Zyvox, Pfizer NYSE:PFE).

The comparative Phase II trial with NXL103 is a prospective, multicenter, investigator-blinded, two-arm, parallel group study carried out in adults, either in hospital or as outpatients, with ABSSSI. Patients will be randomized to receive either NXL103 (500 mg twice a day) or linezolid (600mg twice a day), with 120 patients receiving NXL103 and 60 receiving linezolid. The treatment period in both study arms will be between 10 and 14 days.

The primary endpoint of the study is the clinical outcome in the clinically evaluable population at the Test of Cure (TOC) visit (7 days post-therapy). Secondary end points of the study include microbiological response at the TOC visit as well as evaluating the tolerability and safety of NXL103.

This comparative Phase II study is expected to recruit a total of 180 patients from approximately 20 sites in the USA and Central America. The study is expected to be completed in 2010 and is a critical part of Novexel's clinical development plan for NXL103 which is focused on its potential to be used in hospitals and out-patients as an oral agent for the treatment of infections caused by Gram-positive organisms, including MRSA. Currently, physicians have a limited choice of a
'/>"/>

SOURCE Novexel
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novexel to Present Four Posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases in Helsinki
2. Novexels NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
3. Novexels NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections
4. Novexel to Present Five Posters at the Joint Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Disease Society of America (ICAAC/IDSA) Meeting
5. Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
6. AMT Starts Development LPLChip(TM) With Progenika
7. American Association for Homecare Proposes Strong Anti-Fraud Measures in Medicare, Applauds HHS Testimony Today That Pledges to "Stop Fraud Before it Starts"
8. R-Tech Ueno Starts Early Phase II Clinical Trial for RK-023
9. BioCis Pharma Starts a Phase I Clinical Trial With a New Cancer Drug
10. Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine
11. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2, 2014 , Registry provides ... of life and treatment satisfaction [ 1 ...        (Photo: ... September 2014, Barcelona, Spain : Daiichi ... oF thromboembolic events-European Registry in Atrial Fibrillation (PREFER in ...
(Date:9/2/2014)... 2014  Edison Nation Medical, the premier healthcare ... American Association for Respiratory Care ( AARC ), ... Edison Nation Medical, which brings 12+ years experience ... their innovation ideas, will work with AARC to ... 50,000 respiratory therapists in bringing their product innovation ...
(Date:9/2/2014)... 2, 2014  EMD Serono, Inc., a subsidiary of ... today that Drew Young has joined the ... this capacity, he will be responsible for leading the ... including future products.   Bringing more than 20 ... sales efforts at pharmaceutical and biotech companies, Mr. Young ...
Breaking Medicine Technology:One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 2One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 3One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 4One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 5One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 6One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 7One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 8Edison Nation Medical and AARC Team Up To Promote Innovation in Respiratory Care 2Edison Nation Medical and AARC Team Up To Promote Innovation in Respiratory Care 3EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 2EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 3EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 4
... focus, and new drug-eluting technologies to drive lower extremity ... Millennium Research Group WALTHAM, Mass., May 28 ... for Peripheral Vascular (PV) Devices 2009 report, rapid ... lower extremity peripheral artery disease in Europe is being ...
... MATEO¿ Calif.¿ May 28 Results and additional analyses ... clinical trial of Corthera,s investigational drug relaxin for the ... the Heart Failure Congress, the annual meeting of the ... in Nice, France. Marco Metra, M.D., professor of ...
Cached Medicine Technology:Lower Extremity Peripheral Vascular Stent and Balloon Catheter Markets to Exceed $180 Million in Europe by 2013 2Lower Extremity Peripheral Vascular Stent and Balloon Catheter Markets to Exceed $180 Million in Europe by 2013 3Results and Additional Analyses From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009 2
(Date:9/2/2014)... be a new salve to dominate medicine cabinets of the ... Salamanders may not be the cuddliest of animals, but they ... damaged body parts. Now, a new report published in the ... , identifies a small protein (called a "peptide") from the ... the secret of this amazing wound healing trick in humans. ...
(Date:9/2/2014)... made it clear that a mother,s eating habits prior ... profound impact on her offspring and their propensity for ... the mechanisms behind this phenomenon were unclear. According to ... The FASEB Journal F , scientists using ... mother,s diet and an offspring,s risk of future obesity. ...
(Date:9/2/2014)... 2014 Concorde Career College North ... receive the 2014 Excellence in Community Service Award ... Colleges (ACCSC). , Every year, the Accrediting Commission ... who make outstanding contributions in their local community ... the scope and impact of the community service ...
(Date:9/2/2014)... that the key to more youthful immune function might ... published in the Journal of Leukocyte Biology ... of old mice had different responses to Mycobacterium ... changes were reversed by ibuprofen. , "Inflammation in old ... Joanne Turner, Ph.D., a researcher involved in the work ...
(Date:9/2/2014)... Splashtop Inc. , the worldwide ... NTT DoCoMo to deliver Splashtop Business Lite ... Lite is included in NTT DoCoMo’s “Business Plus” program. ... that empower users to remote access their corporate computers ... 18 million users worldwide. Splashtop delivers the best ...
Breaking Medicine News(10 mins):Health News:Salamander skin peptide promotes quick and effective wound healing in mice 2Health News:How genes link a mother's diet to the risk of obesity in her offspring 2Health News:Concorde Career College North Hollywood Awarded 2014 Excellence in Community Service Award 2Health News:Splashtop and NTT DoCoMo Partner to Deliver “Splashtop Business Lite” Secure Remote Access Solution to Business Customers 2
... Barbara Davis Center for Childhood Diabetes at the University ... against type 1 diabetes: The Juvenile Diabetes Research Foundation ... JDRF Autoimmunity Center at the Barbara Davis Center for ... Autoimmunity Center will receive approximately $1 million a year ...
... are lucky in love. , At least thats how ... research on the mating habits and nervous systems of ... both the voles behavior and their brains, appears in ... Academy of Sciences. , Prairie voles, aka Microtus ochrogaster, ...
... 28 The Department of,Veterans Affairs (VA) today ... Marion, Ill., hospital. The VA today released the ... at the Marion,facility., VA,s Inspector General was ... for Health, on September 10, 2007 and also ...
... Reasons for the association are unknown, researchers say , , ... Korean study found frequent snoring was associated with the ... they aren,t sure why. , "The mechanisms underlying the ... said the report, published in the Jan. 28 issue ...
... to Launch Vitals.com Which Offers Free Comprehensive Doctor ... Information and ... ), one of the,nation,s top 10 public relations firms, today announced ... and execute a,comprehensive communications program for the free, online doctor evaluation,service., ...
... the use of financial,incentives for health care ... non-profit National Business,Coalition on Health (NBCH) recently ... discuss an emerging trend in employer-sponsored health,care: ... choice of,healthier lifestyles and high value medical ...
Cached Medicine News:Health News:JDRF to establish an autoimmunity center at University of Colorado Denver 2Health News:Zoologists: Lusty voles, mindless of danger, mate like rabbits 2Health News:Zoologists: Lusty voles, mindless of danger, mate like rabbits 3Health News:VA Leadership Vows to Fix Problems Identified at Marion VA Medical Center 2Health News:VA Leadership Vows to Fix Problems Identified at Marion VA Medical Center 3Health News:VA Leadership Vows to Fix Problems Identified at Marion VA Medical Center 4Health News:Study Links Snoring to Chronic Bronchitis 2Health News:MWW Group Selected by First-Ever Online Doctor Evaluation Service Vitals.com 2Health News:National Business Coalition on Health Convenes Multi-Stakeholder Leadership Group to Address Value Based Purchasing Trends 2
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
... 3-Point® Polycentric Hinged Ulnar Deviation Splint ... align the hand with ulnar deviation at ... impede grasp or pinch. Radial and ulnar ... ensure unimpeded flexion and extension. Padded, malleable ...
... immobilizes and positions the elbow at 122 ... prominent. Restricts full extension and flexion to ... helps prevent pain and irritation due to ... post-cast removal. Rigid, high-density beige polyethylene shell ...
... Orthosis For quick, efficient immobilization of ... immobilizes and protects the fracture and ... comfort, support, and conformity to the ... shell may be gently heated (with ...
Medicine Products: